About: Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
Creator	Zhang, Qiang Gao, Hainv Li, Lanjuan Chen, Lijun Tang, Lingling Xiang, Charlie Xu, Xiaowei Li, Dong Wang, Baohong Zhou, Chenliang Zhou, Xiaoyang Zhu, Mengfei Wu, Xiaojun Chen, Xiaobei Jiang, Wanli Jiang, Yingan Qu, Jingjing Xu, Zhenyu Ye, Peng
source	Medline; PMC
abstract	The Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O(2) (FiO(2)) of the two patients gradually decreased while the oxygen saturation (SaO(2)) and partial pressure of oxygen (PO(2)) improved. Additionally, the patients’ chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1007/s11684-020-0810-9
bibo:pmid	32761491
has license	no-cc
sha1sum (hex)	7020252ef83e60941dfcc3f28bf9e47e6a3e07f3
schema:url	https://doi.org/10.1007/s11684-020-0810-9
resource representing a document's title	Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
has PubMed Central identifier	PMC7406954
has PubMed identifier	32761491
schema:publication	Front Med
resource representing a document's body	covid:7020252ef83e60941dfcc3f28bf9e47e6a3e07f3#body_text
is schema:about of	named entity 'patients' named entity 'infusion' named entity 'COVID-19' named entity 'symptoms' named entity 'bilateral' named entity 'lymphocytes' named entity 'adsorbed' named entity 'lung' named entity 'confirmed' named entity 'alternative' named entity 'acute respiratory distress syndrome (ARDS)' named entity 'patients' named entity 'ARDS' named entity 'symptom' named entity 'MSCs' named entity 'SARS-CoV' named entity 'menstrual blood' named entity 'monocyte chemoattractant protein-1' named entity 'protein' named entity 'immunostimulants' named entity 'X-rays' named entity 'exudate' named entity 'China' named entity 'Wuhan' named entity 'support' named entity 'dyspnea' named entity 'initial' named entity 'Clinical' named entity 'inflammation' named entity 'clinical data' named entity 'ARDS' named entity 'COVID' named entity 'Wuhan' named entity 'MSC' named entity 'ARDS' named entity 'COVID-19' named entity 'MSC' named entity 'lymphocytes' named entity 'treatment of patients' named entity 'COVID' named entity 'nucleic acid test' named entity 'viral pneumonia' named entity 'COVID' named entity 'epidemics' named entity 'respiratory failure' named entity 'big issue' named entity 'ARDS' named entity 'interleukin-6' named entity 'clinical research' named entity 'epidemic' named entity 'MSC' named entity 'cough' named entity 'MSCs' named entity 'COVID' named entity 'clinical trial' named entity 'SARS-CoV-2' named entity 'blood pressure' named entity 'CRP' named entity 'menstrual blood' named entity 'fever' named entity 'liquid nitrogen' named entity 'hypertension' named entity 'nucleic acid detection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software